- Conditions
- Influenza, Respiratory Syncytial Viruses, Paramyxoviridae Infections, Coronavirus, Rhinovirus
- Interventions
- N95 Respirator, Medical/surgical mask
- Device
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 2,862 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2018
- U.S. locations
- 7
- States / cities
- Aurora, Colorado • Denver, Colorado • Washington D.C., District of Columbia + 3 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–16
of 16
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Percutaneous Coronary Intervention, Peripheral Endovascular Intervention
- Interventions
- Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL, Normal Saline (Placebo)
- Drug
- Lead sponsor
- Duke University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 6,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 149
- States / cities
- Alexander City, Alabama • Birmingham, Alabama • Huntsville, Alabama + 131 more
- Conditions
- Covid19
- Interventions
- rNAPc2, Heparin
- Drug
- Lead sponsor
- ARCA Biopharma, Inc.
- Industry
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 160 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 11
- States / cities
- Fairhope, Alabama • Phoenix, Arizona • Tucson, Arizona + 8 more
- Conditions
- Heart Failure
- Interventions
- Finerenone, Placebo
- Drug
- Lead sponsor
- Colorado Prevention Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 2,600 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 54
- States / cities
- Fairhope, Alabama • Phoenix, Arizona • Yuma, Arizona + 45 more
- Conditions
- Cardiovascular Disease, Myocardial Infarction, Stroke, Coronary Revascularization
- Interventions
- Evolocumab, Routine Lipid Management
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 6,019 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 81
- States / cities
- Birmingham, Alabama • Fairhope, Alabama • Huntsville, Alabama + 73 more
- Conditions
- Peripheral Vascular Disease, Intermittent Claudication, Peripheral Arterial Disease
- Interventions
- Levocarnitine tartrate, cilostazol
- Dietary Supplement · Drug
- Lead sponsor
- Colorado Prevention Center
- Other
- Eligibility
- 40 Years and older
- Enrollment
- 164 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2010
- U.S. locations
- 24
- States / cities
- Phoenix, Arizona • Little Rock, Arkansas • Palo Alto, California + 18 more
- Conditions
- Heart Failure
- Interventions
- Finerenone, Empagliflozin
- Drug
- Lead sponsor
- Colorado Prevention Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1,500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 46
- States / cities
- Fairhope, Alabama • Phoenix, Arizona • Chula Vista, California + 40 more
- Conditions
- Type 1 Diabetes
- Interventions
- iBGStar meter
- Device
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012 – 2013
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
- Conditions
- Hyperlipidemia
- Interventions
- Algorithm- and multi-professional team-supported lipid management, Guideline-directed lipid management by usual care provider
- Other
- Lead sponsor
- Colorado Prevention Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
- Conditions
- Peripheral Vascular Diseases, Intermittent Claudication
- Interventions
- Propionyl-L-Carnitine, PLC
- Drug
- Lead sponsor
- Sigma-Tau Research, Inc.
- Industry
- Eligibility
- 40 Years to 80 Years
- Enrollment
- 69 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2008
- U.S. locations
- 9
- States / cities
- Jacksonville, Florida • Pensacola, Florida • LaGrange, Illinois + 6 more
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Virta Health
- Behavioral
- Lead sponsor
- Colorado Prevention Center
- Other
- Eligibility
- 18 Years to 79 Years
- Enrollment
- 51 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2024
- U.S. locations
- 3
- States / cities
- Craig, Colorado • Lamar, Colorado • Salida, Colorado
- Conditions
- Acute Heart Failure
- Interventions
- 6 Minute Walk Test
- Procedure
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 51 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 6
- States / cities
- Indianapolis, Indiana • Detroit, Michigan • Winston-Salem, North Carolina + 2 more
- Conditions
- Peripheral Artery Disease
- Interventions
- Intervention A - Vascular Care + site 6MWT administration, Intervention B - Standard Care + site 6MWT administration, Intervention A - Vascular Care + CPC EQuIP 6MWT administration, Intervention B - Standard Care + CPC EQuIP 6MWT administration
- Other
- Lead sponsor
- Colorado Prevention Center
- Other
- Eligibility
- Not listed
- Enrollment
- 166 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
- Conditions
- Heart Failure, Acute Heart Failure
- Interventions
- Finerenone, Placebo
- Drug
- Lead sponsor
- Colorado Prevention Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 5,200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 82
- States / cities
- Birmingham, Alabama • Fairhope, Alabama • Huntsville, Alabama + 72 more
- Conditions
- Peripheral Artery Disease
- Interventions
- Rivaroxaban (Xarelto, BAY59-7939), Rivaroxaban-Placebo
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 6,564 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2020
- U.S. locations
- 105
- States / cities
- Alexander City, Alabama • Birmingham, Alabama • Fort Payne, Alabama + 91 more
- Conditions
- Peripheral Arterial Disease, Angina
- Interventions
- Ranolazine, Placebo
- Drug
- Lead sponsor
- Colorado Prevention Center
- Other
- Eligibility
- 40 Years and older · Male only
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 3
- States / cities
- Aurora, Colorado • Denver, Colorado